APPL1 and osteoporosis: In this study, we found that APPL1 was able to enhance osteogenic differentiation of MSCs in vitro and reduced glucocorticoid-induced bone loss in vivo, highlighting its potential use may be an alternative drug to treat osteoporosis by modulating osteogenic differentiation.